Rucosopasem manganese(Synonyms: GC4711)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Rucosopasem manganese (Synonyms: GC4711)

Rucosopasem manganese (GC4711) 是一种选择性超氧化物歧化酶模拟物,可将超氧化物转化为过氧化氢。Rucosopasem manganese 可用于癌症研究。

Rucosopasem manganese(Synonyms: GC4711)

Rucosopasem manganese Chemical Structure

CAS No. : 2248030-85-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Rucosopasem manganese (GC4711) is a selective superoxide dismutase mimetic that converts superoxide to hydrogen peroxide. Rucosopasem manganese can be used for the research of cancer[1].

体外研究
(In Vitro)

Rucosopasem manganese (GC4711) is a selective superoxide dismutase mimetic that converts superoxide to hydrogen peroxide[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

558.62

Formula

C27H45MnN5O4

CAS 号

2248030-85-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Rucosopasem manganese(Synonyms: GC4711)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Rucosopasem manganese (Synonyms: GC4711)

Rucosopasem manganese (GC4711) 是一种选择性超氧化物歧化酶模拟物,可将超氧化物转化为过氧化氢。Rucosopasem manganese 可用于癌症研究。

Rucosopasem manganese(Synonyms: GC4711)

Rucosopasem manganese Chemical Structure

CAS No. : 2248030-85-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Rucosopasem manganese (GC4711) is a selective superoxide dismutase mimetic that converts superoxide to hydrogen peroxide. Rucosopasem manganese can be used for the research of cancer[1].

体外研究
(In Vitro)

Rucosopasem manganese (GC4711) is a selective superoxide dismutase mimetic that converts superoxide to hydrogen peroxide[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

558.62

Formula

C27H45MnN5O4

CAS 号

2248030-85-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Rucosopasem manganese(Synonyms: GC4711)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Rucosopasem manganese (Synonyms: GC4711)

Rucosopasem manganese (GC4711) 是一种选择性超氧化物歧化酶模拟物,可将超氧化物转化为过氧化氢。Rucosopasem manganese 可用于癌症研究。

Rucosopasem manganese(Synonyms: GC4711)

Rucosopasem manganese Chemical Structure

CAS No. : 2248030-85-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Rucosopasem manganese (GC4711) is a selective superoxide dismutase mimetic that converts superoxide to hydrogen peroxide. Rucosopasem manganese can be used for the research of cancer[1].

体外研究
(In Vitro)

Rucosopasem manganese (GC4711) is a selective superoxide dismutase mimetic that converts superoxide to hydrogen peroxide[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

558.62

Formula

C27H45MnN5O4

CAS 号

2248030-85-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Imisopasem manganese(Synonyms: M40403; GC4403)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Imisopasem manganese (Synonyms: M40403; GC4403) 纯度: ≥96.0%

Imisopasem manganese (M40403) 是稳定的 MnSOD 的非肽基模拟物。

Imisopasem manganese(Synonyms: M40403;  GC4403)

Imisopasem manganese Chemical Structure

CAS No. : 218791-21-0

规格 价格 是否有货 数量
10 mM * 1 mL in Water ¥1793 In-stock
2 mg ¥990 In-stock
5 mg ¥1700 In-stock
10 mg ¥2700 In-stock
25 mg ¥5400 In-stock
50 mg ¥8500 In-stock
100 mg ¥11500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Imisopasem manganese 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Drug Repurposing Compound Library

生物活性

Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.

体外研究
(In Vitro)

Imisopasem manganese is a small molecule, synthetic manganese containing superoxide dismutase mimetic (SODm) that removes superoxide anions without interfering with other reactive species known to be involved in inflammatory responses (e.g. nitric oxide, NO and peroxynitrite, ONOO-)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Imisopasem manganese is a small-molecule superoxide dismutase mimetic that has shown efficacy in animal model disease states in which superoxide anions are thought to play a key role. Imisopasem manganese inhibits the inflammatory response following the intrapleural injection of carrageenan in rats. All parameters of inflammation are attenuated by Imisopasem manganese except for NOx, PGE2 and IL-10 which remains unaltered[1]. Decreased apoptosis of the large and particularly the small bowel and marked recovery of both lymphoid and hematopoietic tissues occurs in the Imisopasem manganese pre-treated mice. Imisopasem manganese is effective in reducing TBI-induced tissue destruction and has potential as a new radioprotective agent[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

479.35

Formula

C21H31Cl2MnN5

CAS 号

218791-21-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 16 mg/mL (33.38 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0862 mL 10.4308 mL 20.8616 mL
5 mM 0.4172 mL 2.0862 mL 4.1723 mL
10 mM 0.2086 mL 1.0431 mL 2.0862 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Salvemini D, et al. Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic,M40403. Br J Pharmacol. 2001 Feb;132(4):815-27.

    [2]. Masini E, et al. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol. 2002 Jul;136(6):905-17.

Animal Administration
[1][2]

Rats: Male Sprague-Dawley rats are used in the study. M40403 (5-20 mg kg-1), or an equivalent volume (0.3 mL) of vehicle (26 mm sodium bicarbonate buffer, pH 8.1-8.3), is injected intraperitoneally (i.p.) 15 min before carrageenan. At 4 h after the injection of carrageenan, the animals are killed by inhalation of CO2[1].

Mice: 30 mg dry powder M40403 is dissolved in 6.0 ml SBC adjusted to pH 8.3 with 1 M NaOH. This stock solution is diluted to 1.25 mg/mL in SBC. Two experimental models are tested. In one, the dose of IR is held constant at 8.5 Gy total body irradiation (TBI). The mice are injected i.p. with a single dose of 40 mg/kg, 30 mg/kg, 20 mg/kg or 10 mg/kg M40403. Thirty minutes later the mice receives 8.5 Gy total body irradiation (TBI). Control animals receives 0.1 ml of SBC buffer prior to TBI. In the other model, groups of 20 mice receives either 6.5 or 7.5 Gy TBI. One half of each group is treated with 2.0 mg/kg M40403 i.p. and the other with SBC 30 min before TBI. All are followed for survival[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Salvemini D, et al. Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic,M40403. Br J Pharmacol. 2001 Feb;132(4):815-27.

    [2]. Masini E, et al. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol. 2002 Jul;136(6):905-17.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Avasopasem manganese(Synonyms: GC-4419; M-40419)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Avasopasem manganese (Synonyms: GC-4419; M-40419)

Avasopasem manganese (GC4419;M-40419) 是一种有效的超氧化物歧化酶,能迅速和特异性地将 O2*- 转化为过氧化氢 (H2O2),阻止这一级联反应的启动。Avasopasem manganese 可用于严重口腔黏膜炎 (SOM) 和癌症的研究。

Avasopasem manganese(Synonyms: GC-4419;  M-40419)

Avasopasem manganese Chemical Structure

CAS No. : 435327-40-5

规格 价格 是否有货
5 mg ¥8000 询问价格 & 货期
10 mg ¥13000 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Avasopasem manganese (GC4419; M-40419) is a potent superoxide dismutase mimetic that rapidly and specifically converts O2*- to hydrogen peroxide (H2O2), arresting the initiation of this cascade. Avasopasem manganese can be used for the research of severe oral mucositis (SOM) and cancer[1].

体内研究
(In Vivo)

Avasopasem manganese is an agent intended to interrupt severe oral mucositis pathogenesis, to reduce the duration, incidence, and severity of radiation-induced oral mucositis[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

479.35

Formula

C21H31Cl2MnN5

CAS 号

435327-40-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Anderson CM, et al. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer [published correction appears in J Clin Oncol. 2020 Jan 20;38(3):288]. J Clin Oncol. 2019;37(34):3256-3265.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务